Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy

Area of Science:

• Biomedical Engineering
• Cancer Immunology
• Drug Delivery Systems

Background:

• Immunotherapy has transformed cancer treatment but faces challenges like low response rates and immune-related adverse events.
• Targeting immunomodulatory drugs to specific tissues can enhance efficacy and minimize side effects.
• Lymphatic tissues play a crucial role in immunotherapy response, driving interest in targeted delivery strategies.

Purpose of the Study:

• To review drug delivery systems (DDSs) engineered for targeted delivery of immunomodulators to lymphatic tissues.
• To highlight how these DDS platforms can augment cancer immunotherapy by improving drug uptake and immune modulation.
• To discuss the application of DDSs in delivering cancer vaccines, chemotherapeutics, immune checkpoint blockade (ICB) antibodies, and lymphangiogenic factors.

Main Methods:

• Review of existing literature on DDS platforms for lymphatic targeting.
• Analysis of DDS mechanisms for enhanced uptake into lymphatic vessels and lymph nodes.
• Examination of how DDSs facilitate the delivery of various immunotherapeutics and modulators.

Main Results:

• Various DDS platforms demonstrate efficient uptake into lymphatic tissues for targeted immune modulation.
• DDSs enable the delivery of cancer vaccines, chemotherapeutics, and ICB antibodies to lymphatic sites.
• Targeted delivery via DDSs can modulate lymphatic vasculature and augment anti-cancer immune responses.

Conclusions:

• Engineered DDSs offer a promising strategy to overcome immunotherapy limitations by enabling targeted delivery to lymphatic tissues.
• These systems can enhance therapeutic efficacy and reduce adverse events in cancer treatment.
• DDS-mediated delivery to lymphatic tissues represents a key advancement in augmenting cancer immunotherapy.